Provided by Tiger Fintech (Singapore) Pte. Ltd.

Celldex Therapeutics

21.21
-0.2300-1.07%
Volume:841.05K
Turnover:17.73M
Market Cap:1.41B
PE:-7.86
High:21.66
Open:21.45
Low:20.73
Close:21.44
52wk High:47.00
52wk Low:14.40
Shares:66.39M
Float Shares:52.89M
Volume Ratio:0.98
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6987
EPS(LYR):-2.4515
ROE:-23.20%
ROA:-16.88%
PB:2.00
PE(LYR):-8.65

Loading ...

Celldex Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 09

UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating

MT Newswires Live
·
May 09

Celldex price target lowered to $38 from $44 at UBS

TIPRANKS
·
May 09

Stock Track | Celldex Therapeutics Plummets 6.76% as Morgan Stanley Cuts Target Price

Stock Track
·
May 09

Celldex Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 09

Celldex Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 09

Celldex Therapeutics Q1 EPS $(0.81) Misses $(0.74) Estimate, Sales $695.00K Miss $1.05M Estimate

Benzinga
·
May 09

Celldex Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview

Reuters
·
May 06

Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
May 06

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

GlobeNewswire
·
May 06

Canada's Northern Graphite plans to put Quebec mine on care and maintenance

Reuters
·
May 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

Celldex Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Apr 28

BUZZ-U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli Lilly

Reuters
·
Mar 20

BUZZ-U.S. STOCKS ON THE MOVE-Five Below, QXO, PDD Holdings

Reuters
·
Mar 20

BUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment

Reuters
·
Mar 20

Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target

MT Newswires Live
·
Mar 20

Celldex Therapeutics Initiated at Overweight by Morgan Stanley

Dow Jones
·
Mar 20

Celldex Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
Mar 04

Celldex Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Mar 03